Véronique Joly

3.0k total citations
63 papers, 1.0k citations indexed

About

Véronique Joly is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Véronique Joly has authored 63 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Infectious Diseases, 29 papers in Virology and 16 papers in Epidemiology. Recurrent topics in Véronique Joly's work include HIV/AIDS drug development and treatment (33 papers), HIV Research and Treatment (29 papers) and HIV/AIDS Research and Interventions (20 papers). Véronique Joly is often cited by papers focused on HIV/AIDS drug development and treatment (33 papers), HIV Research and Treatment (29 papers) and HIV/AIDS Research and Interventions (20 papers). Véronique Joly collaborates with scholars based in France, Martinique and Vietnam. Véronique Joly's co-authors include P. Yéni, Patrick Yéni, Jacques Bolard, C Carbon, Françoise Brun‐Vézinet, Diane Descamps, Allan J. Hance, Jacques Izopet, Monique Chéron and Claude Fortin and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Journal of Virology.

In The Last Decade

Véronique Joly

61 papers receiving 977 citations

Peers

Countries citing papers authored by Véronique Joly

Since Specialization

Citations

This map shows the geographic impact of Véronique Joly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Véronique Joly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Véronique Joly more than expected).

Fields of papers citing papers by Véronique Joly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Véronique Joly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Véronique Joly. The network helps show where Véronique Joly may publish in the future.

Co-authorship network of co-authors of Véronique Joly

This figure shows the co-authorship network connecting the top 25 collaborators of Véronique Joly. A scholar is included among the top collaborators of Véronique Joly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Véronique Joly. Véronique Joly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Brief Report: Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France 2022 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Yousra Kherabi, Nathalie De Castro, Pierre‐Olivier Sellier, (unknown), (unknown), F. Méchaï, Véronique Joly, Yazdan Yazdanpanah, Jean‐Michel Molina	0
2	New Kaposi’s sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies 2020 ·The Journal of Infectious Diseases ·Aude Jary, Valentin Leducq, Nathalie Désiré, Héloïse Petit, Romain Palich, Véronique Joly, Ana Canestri, (unknown), Sidonie Lambert-Niclot, Laure Surgers, Corinne Amiel, Diane Descamps, Jean‐Philippe Spano, Christine Katlama, Vincent Cálvez, Anne‐Geneviève Marcelin	18
3	Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection 2019 ·PLoS ONE ·Pierre Gantner, Laurent Cotte, Clotilde Allavena, Firouzé Bani‐Sadr, Thomas Huleux, Claudine Duvivier, Marc‐Antoine Valantin, Christine Jacomet, Véronique Joly, Antoine Chéret, Pascal Puglièse, Pierre Delobel, André Cabié, David Rey, (unknown)	18
4	Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France 2018 ·Médecine et Maladies Infectieuses ·P. Puglièse, Véronique Joly, M.A. Valantin, Laurent Cotte, T. Huleux, Clotilde Allavena, Jacques Reynes, Isabelle Poizot‐Martin, Firouzé Bani‐Sadr, Lise Cuzin	1
5	Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort 2017 ·Journal of Antimicrobial Chemotherapy ·Marine Perrier, Charlotte Charpentier, Gilles Peytavin, Minh Lê, (unknown), Benoît Visseaux, Véronique Joly, (unknown), Sophie Matheron, Yazdan Yazdanpanah, Diane Descamps, Roland Landman	7
6	Epidemiological Profile of Newly Diagnosed HIV-Infected Patients in Northern Paris: A Retrospective Study 2016 ·AIDS Research and Human Retroviruses ·Olivia Sénard, Charles Burdet, Benoît Visseaux, Charlotte Charpentier, Sylvie Le Gac, Zélie Julia, Sylvie Lariven, Diane Descamps, Yazdan Yazdanpanah, Patrick Yéni, Véronique Joly	4
7	Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up 2015 ·PLoS ONE ·Charlotte Charpentier, Minh Lê, Véronique Joly, Benoît Visseaux, Sylvie Lariven, Bao Phung, Patrick Yéni, Yazdan Yazdanpanah, Diane Descamps, Gilles Peytavin, Roland Landman	3
8	Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay 2014 ·Journal of Antimicrobial Chemotherapy ·Charlotte Charpentier, (unknown), Véronique Joly, P. Yéni, Benoît Visseaux, Marion Caséris, Françoise Brun‐Vézinet, Yazdan Yazdanpanah, Gilles Peytavin, Diane Descamps, (unknown)	9
9	Predictive Value of Liver Enzymes and Inflammatory Biomarkers for the Severity of Liver Fibrosis Stage in HIV/HCV Co-Infected Patients 2013 ·PLoS ONE ·Charlotte Charpentier, Karen Champenois, Anne Gervais, Roland Landman, Véronique Joly, Sylvie Le Gac, Lucile Larrouy, Florence Damond, Françoise Brun‐Vézinet, Diane Descamps, Yazdan Yazdanpanah	10
10	Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome 2012 ·Journal of Antimicrobial Chemotherapy ·C. Charpentier, (unknown), Cédric Laouenan, Véronique Joly, (unknown), Florence Damond, Françoise Brun‐Vézinet, France Mentré, Diane Descamps, P. Yéni	37
11	Enfuvirtide: from basic investigations to current clinical use 2010 ·Expert Opinion on Pharmacotherapy ·Véronique Joly, Kaoutar Jidar, Mercedes Tatay, Patrick Yéni	31
12	Emerging reverse transcriptase inhibitors for the treatment of HIV infection in adults 2006 ·Expert Opinion on Emerging Drugs ·Claude Fortin, Véronique Joly, Patrick Yéni	3
13	Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073) 2004 ·Journal of Clinical Virology ·Diane Descamps, Véronique Joly, Philippe Flandre, Gilles Peytavin, Vincent Meiffrédy, Séverine Mercier‐Delarue, Stéphane Lastère, J Aboulker, Patrick Yéni, Françoise Brun‐Vézinet	4
14	Effect of Zidovudine Resistance Mutations on Virologic Response to Treatment With Zidovudine or Stavudine, Each in Combination With Lamivudine and Indinavir 2002 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Diane Descamps, Philippe Flandre, Véronique Joly, Vincent Meiffrédy, Gilles Peytavin, Jacques Izopet, Catherine Tamalet, (unknown), (unknown), Stéphane Lastère, J Aboulker, Patrick Yéni, Françoise Brun‐Vézinet	9
15	On the Use of Magnitude of Reduction in HIV-1 RNA in Clinical Trials: Statistical Analysis and Potential Biases 2002 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Philippe Flandre, Christine Durier, Diane Descamps, Odile Launay, Véronique Joly	15
16	Comparative evaluation over a six-month experience of postexposure antiretroviral treatment for occupational and non-occupational exposures to HIV 1998 ·(unknown), Enrique Casalino, Sophie Matheron, (unknown), Véronique Joly, P. Longuet, F. Bouscarat, Agnès Certain, E. Bouvet	1
17	Amphotéricine B : ancien médicament, nouveaux concepts 1997 ·Jacques Bolard, Véronique Joly, Patrick Yéni	2
18	Pacemaker Endocarditis Due to Candida albicans: Case Report and Review 1997 ·Clinical Infectious Diseases ·Véronique Joly, Nadia Belmatoug, (unknown), J. Robert, F Jault, Claude Carbón, Patrick Yéni	32
19	Inhibiting Cholesterol Synthesis Reduces the Binding and Toxicity of Amphotericin B against Rabbit Renal Tubular Cells in Primary Culture 1992 ·The Journal of Infectious Diseases ·Véronique Joly, M. Saint-Pierre-Chazalet, (unknown), Jacques Bolard, Claude Carbón, Patrick Yéni	18
20	Incorporation of amphotericin B (AMB) into liposomes alters AMB-induced acute nephrotoxicity in rabbits. 1989 ·Journal of Pharmacology and Experimental Therapeutics ·Véronique Joly, Françoise Dromer, (unknown), P. Yéni, Nathalie Séta, (unknown), C Carbon	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact